CYP2S1 and thyroid gland carcinoma: Thus, our data demonstrate that CYP2S1 is a potential synthetic lethal partner of BRAFV600E, and also provide an alternative therapeutic strategy for BRAFV600E-mutated thyroid cancers by targeting CYP2S1.